The introduction of nicotinamide being a nicotine substitution in e-cigarette and smokeless products and solutions represents a substantial regulatory problem to the FDA. Nicotinamide does not have nicotinic receptor agonist activity and is understood to work as a sedative at large dosages6. The cla